CoChat
Sign Up
Cited by 272Reproductive Health and ContraceptionSperm and Testicular FunctionHypothalamic control of reproductive hormones

The DOI matches its Crossref record; 78 of the 79 references it cites were found in a registry or an index.

Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis

Liu, Peter Y, Swerdloff, Ronald S, Christenson, Peter D, Handelsman, David J, Wang, Christina·2006·The Lancet
DOI 10.1016/s0140-6736(06)68614-5
Open this paper in CoChat — free account

Abstract

Background Hormonal methods for safe, reliable, and reversible contraception based on the suppression of spermatogenesis could soon become available. We have investigated the rate, extent, and predictors of reversibility of hormonal male contraception.Methods We undertook an integrated multivariate time-to-event analysis of data from individual participants in 30 studies published in 1990-2005, in which sperm output was monitored every month until recovery. The primary outcome was the time for the sperm concentration to recover to a threshold of 20 million per mL, an indicator of fertility. We undertook univariate and multivariate analyses, using Kaplan-Meier and Cox's methods.Findings 1549 healthy eugonadal men who were white (n=965), Asian (almost all Chinese men; n=535), or of other origins (n=49) and aged 18-51 years underwent 1283.5 man-years of treatment and 705 man-years of post-treatment recovery. These data represented about 90% of all published data from individuals using androgen or androgen-progestagen regimens. The median times for sperm to recover to thresholds of 20, 10, and 3 million per mL were 3.4 months (95% CI 3.2-3.5), 3.0 months (2.9-3.1), and 2.5 months (2.4-2.7), respectively. Multivariate Cox's analysis showed higher rates of recovery with older age, Asian origin, shorter treatment duration, shorter-acting testosterone preparations, higher sperm concentrations at baseline, faster suppression of spermatogenesis, and lower blood concentrations of luteinising hormone at baseline. The typical probability of recovery to 20 million per mL was 67% (61-72) within 6 months, 90% (85-93) within 12 months, 96% (92-98) within 16 months, and 100% within 24 months.Interpretation Hormonal male contraceptive regimens show full reversibility within a predictable time course. Various covariables affect the rate but not the extent of recovery, although their effect sizes are minor. These data are crucial for the further safe and practical development of such regimens.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(06)68614-5

Cites

78 of 78 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

Sorted by citations

See all 272

Related

See all

Metadata

Authors
Liu, P. Y., Swerdloff, R. S., Christenson, P. D., Handelsman, D. J., & Wang, C.
Affiliations
  • The University of Sydney (AU)
  • The Lundquist Institute (US)
Corresponding author
Liu, Peter Y
ORCID
Venue
The Lancet
Publisher
Elsevier BV
Published
2006-04
Volume
367
Issue
9520
Pages
1412-1420
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
DOI
10.1016/s0140-6736(06)68614-5
OpenAlex
W2144125198
Cited by
272
References
79
Citations by year
2026: 13 · 2025: 8 · 2024: 24 · 2023: 24 · 2022: 20 · 2021: 15 · 2020: 15 · 2019: 17 · 2018: 14 · 2017: 19 · 2016: 15 · 2015: 11 · 2014: 8 · 2013: 10 · 2012: 14
FWCI
8.62
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
  • Research Explorer (The University of Manchester) (submittedVersion)
Funders
  • Institut National de la Santé et de la Recherche Médicale
  • National Institutes of Health
  • National Health and Medical Research Council
  • National Medical Research Council
  • National Center for Research Resources (M01RR000425, RR M01 00425)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
  • Health Sciences › Medicine › Reproductive Medicine › Sperm and Testicular Function
  • Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
Keywords
androgen deprivation therapy, testosterone, sperm concentration, luteinizing hormone, predictors of recovery, time to recovery
MeSH terms
Adult, Androgen Antagonists, Androgens, Clinical Trials as Topic, Contraception, Humans, Male, Middle Aged, Prospective Studies, Sperm Count, Spermatogenesis, Spermatogenesis-Blocking Agents, Testosterone, Time Factors, Multicenter Studies as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review